Ecnoglutide DDI Data Clears Co-Administration Path for Novel GLP-1 Analogue
Executive Summary
Ecnoglutide, a novel cAMP-biased glucagon-like peptide-1 (GLP-1) analogue from China’s Sciwind Biosciences, has cleared a key pharmacokinetic hurdle. A Phase 1 drug–drug interaction (DDI) study published June 17 in Diabetes, Obesity & Metabolism shows no clinically significant interactions with rosuvastatin or digoxin, meaning no dose adjustments are required for these commonly co-prescribed drugs. The study also confirmed the peptide’s potent weight-loss effect: a mean 11.2% body weight reduction across just 14 weeks in healthy volunteers. This DDI clearance removes one of the final pre-approval unknowns for a molecule that already has two positive Phase 3 trials in the Lancet — one in type 2 diabetes (EECOH-2, non-inferior to dulaglutide) and one in obesity (significant weight loss vs placebo).
Context
The GLP-1 receptor agonist market — projected to exceed $150 billion by 2030 — is dominated by two behemoths: Novo Nordisk’s semaglutide (Ozempic/Wegovy) and Eli Lilly’s tirzepatide (Mounjaro/Zepbound). But the pipeline is far from static. A wave of next-generation candidates is advancing, each claiming differentiation on dosing frequency, receptor bias, or combinatorial pharmacology. Ecnoglutide’s distinguishing feature is cAMP-biased agonism: by preferentially activating the Gαs/cAMP signaling pathway over β-arrestin recruitment, the molecule aims to preserve glycemic and weight-loss efficacy while potentially reducing receptor desensitization and tachyphylaxis — a subtle but meaningful advantage in chronic therapy.
Sciwind Biosciences, headquartered in Hangzhou, has been methodically building the ecnoglutide dossier. The Phase 2 data, published in Nature Communications (2024), established glycemic efficacy in T2D. Two Phase 3 readouts followed in 2025, both landing in The Lancet Diabetes & Endocrinology. The EECOH-2 trial demonstrated non-inferiority to dulaglutide (Trulicity) in HbA1c reduction over 52 weeks, while the obesity trial produced statistically and clinically significant weight loss versus placebo. The DDI study now addresses a practical clinical question: can doctors safely co-prescribe ecnoglutide with statins (rosuvastatin) and narrow-therapeutic-index drugs (digoxin)? The answer is yes.
The Data
| Parameter | Rosuvastatin (10 mg) | Digoxin (0.25 mg) |
|---|---|---|
| Study design | Open-label, single-sequence crossover, Phase 1; 28 healthy adults | |
| AUC0–∞ GM ratio (with ecnoglutide vs alone) | 106% (90% CI: 94–120%) | 84% (90% CI: 76–94%) |
| Cmax effect | No clinically relevant change | ↓ from 1.39 to 1.31 ng/mL (within therapeutic window) |
| Dose adjustment required? | No | No (monitor in renal impairment) |
| Weight loss (ecnoglutide 1.2 mg SC) | 11.2% mean reduction over 14 weeks | |
| Common AEs | Gastrointestinal (GLP-1 class effect), no serious AEs | |
| Trial | Phase | Population | Key Result | Publication |
|---|---|---|---|---|
| Phase 2 T2D | 2 | Adults with T2D | Significant HbA1c reduction vs placebo | Nature Communications (2024) |
| EECOH-2 | 3 | T2D on metformin | Non-inferior to dulaglutide at 52 weeks | Lancet Diabetes Endocrinol (2025) |
| Obesity Phase 3 | 3 | Overweight/obesity | Significant weight loss vs placebo | Lancet Diabetes Endocrinol (2025) |
| DDI Study | 1 | Healthy volunteers | No clinically relevant PK interactions | Diabetes Obes Metab (2026) |
Expert Insight
Anti-Pattern: Assuming DDI clearance means smooth sailing through regulatory review. The DDI data answers one narrow question — pharmacokinetic compatibility with two probe substrates — but experienced peptide developers know that GLP-1 agonists introduce a more complex absorption challenge than the DDI label suggests. GLP-1 receptor agonists delay gastric emptying, which can alter the absorption kinetics of any orally administered drug, not just those with narrow therapeutic indices. The rosuvastatin and digoxin findings are reassuring for those two drugs specifically, but they do not constitute a general “no interaction” license. Clinicians will need to monitor patients on time-sensitive oral medications (e.g., levothyroxine, certain antibiotics) during ecnoglutide initiation and dose escalation — a nuance that package inserts rarely capture with sufficient granularity.
A second, less obvious concern: the weight-loss data in this DDI study (11.2% in 14 weeks in healthy volunteers) may actually complicate the regulatory narrative. This magnitude of weight loss in a non-diabetic, non-obese population raises the question of how broadly the drug could be used — and how regulators will define the appropriate patient population. The Phase 3 obesity trial enrolled people with BMI ≥30 (or ≥27 with comorbidities); the DDI participants were healthy volunteers with a mean BMI that was presumably lower. If ecnoglutide produces double-digit weight loss even in leaner populations, the safety of long-term use at lower BMI thresholds becomes a legitimate question for regulators, not a marketing advantage.
Frequently Asked Questions
What makes ecnoglutide different from semaglutide or tirzepatide?
Ecnoglutide is a cAMP-biased GLP-1 receptor agonist — it preferentially activates the Gαs/cAMP signaling cascade while producing less β-arrestin recruitment than balanced agonists like semaglutide. The theoretical advantage: sustained signaling with less receptor internalization and desensitization, potentially translating to better long-term glycemic durability. Unlike tirzepatide, it is a single-receptor agonist (GLP-1R only), not a dual GIP/GLP-1 co-agonist. It is also formulated for once-weekly subcutaneous injection, matching the current standard of care.
How does 11.2% weight loss in 14 weeks compare to other GLP-1 drugs?
This is an impressive signal but requires context. Semaglutide 2.4 mg (Wegovy) produced approximately 5–6% weight loss at 12–14 weeks in its Phase 3 STEP trials, reaching ~15% at 68 weeks. Tirzepatide 15 mg showed ~8% at 12 weeks in SURMOUNT-1, reaching ~21% at 72 weeks. Ecnoglutide’s 11.2% at 14 weeks in healthy volunteers (not selected for obesity) is on the high end for this time point. However, this was a DDI study (n=28), not a dedicated weight-loss trial — small sample sizes inflate effect-size variability. The dedicated Phase 3 obesity trial provides the more reliable efficacy benchmark.
Is Sciwind Biosciences positioned to compete with Novo Nordisk and Eli Lilly?
Sciwind is not competing head-to-head with the GLP-1 giants on commercial scale — its more realistic path is partnership or regional market entry. The company has executed a clinical program of impressive quality for a biotech of its size: Phase 2 in Nature Communications, two Phase 3 trials in The Lancet, and methodical DDI characterization. This publication track record suggests a team that understands both drug development and scientific credibility. The most likely near-term scenario: out-licensing ex-China rights to a global pharma partner while retaining China commercialization rights, following the playbook of companies like Innovent (which partnered mazdutide with Lilly).
Further Reading
- CagriSema and the Next Wave: What Novo Nordisk’s Pipeline Means for Obesity Treatment
- The Race to Biosimilar Semaglutide: Who’s Ahead and What It Means for Pricing
- Peptide Drug Approvals by Modality: What 2020–2026 Data Reveal About the Pipeline
Last reviewed: June 2026. Peptide Proof Editorial Team. Source: Li F, Du C, Yu Q, et al. “Effect of a Novel GLP-1 Analogue Ecnoglutide on the Pharmacokinetics of Rosuvastatin and Digoxin in Healthy Participants.” Diabetes, Obesity & Metabolism (2026). doi:10.1111/dom.70880
